Repositive expands CRO network with Pharmatest partnership
Cambridge-based Repositive, which claims “the world’s largest directory of preclinical cancer models,” has expanded its global network of contract research organisation partners with the addition of Pharmatest from Finland.
Pharmatest provides clinically predictive preclinical efficacy services for oncology and skeletal diseases and brings to the partnership more than 20 years of experience in disease modelling.
This enables Repositive to further grow its global reach to serve more biopharma companies in their quest for the right preclinical cancer models to accelerate oncology drug development programmes.
At present, the Repositive Cancer Models Platform displays curated and standardised metadata from over 8,000 preclinical cancer models.
Repositive helps preclinical oncology researchers to speed up their projects by helping them find and source the most suitable cancer models for their needs.
Founded by bioinformatics expert Fiona Nielsen, Repositive partners with contract research organisations (CROs) worldwide to organise and curate their cancer model data, and present their inventory of models online.
Repositive says that by connecting its CRO partners to the researchers who are interested in their models, they are helping to accelerate cancer drug development to bring new treatments and cures to patients. Respositive delivers these services via our online Cancer Models Platform and our expert Cancer Model Scout concierge search service.